Japan launch leaves Taiwan status of ADHD therapy app unverified

Shionogi launched ENDEAVORRIDE in Japan on June 5, 2026 and said it holds the product’s development and commercialization rights in Japan and Taiwan. The announcement identifies Japan as the launch market and does not report a Taiwan authorization or launch. APPI News could not verify an issued Taiwan license or a public filing under ENDEAVORRIDE, EndeavorRx or the named companies as of August 12, 2026. A commercial agreement for a territory does not itself authorize a medical device for sale there.

The gap illustrates why “digital therapeutic” does not have one regulatory status worldwide. Each jurisdiction separately defines the product category, reviews the evidence, authorizes the device and decides whether a public or private payer will cover it.

Digital therapeutic is not a single global category

A 2025 cross-sectional study used a narrow US definition: software-only medical devices with explicit prescription use. It identified 13 prescription digital therapeutics cleared by the US Food and Drug Administration (FDA) through May 2025, with eight using the 510(k) route and five using De Novo classification. The study also found that the authorized wording ranged from direct treatment claims to narrower claims about symptom management or functional improvement.

The total is not a count of every therapeutic app available worldwide. The study excluded nonprescription products, general-wellness software and devices that require hardware beyond a smartphone. Germany’s digital health application directory and Japan’s treatment-support software category therefore cannot be added to the US figure as if all three systems used the same boundary.

Japan’s file combined local and US evidence

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), which reviews medicines and medical devices for the country, received Shionogi’s ENDEAVORRIDE application on February 26, 2024. The PMDA review classified it as software supporting treatment of attention-deficit/hyperactivity disorder and examined two Japanese studies and three US studies. Japan granted marketing authorization in February 2025, and Shionogi launched the product 16 months later.

The Japanese phase 3 study enrolled 164 participants aged six to 17, according to the review record and the company’s launch announcement. PMDA also limited the authorized patient group and required Shionogi to distribute proper-use guidance prepared by relevant Japanese academic societies. This product-specific file shows a local regulator reassessing foreign and domestic evidence, but it does not establish a universal requirement to repeat the same trial in every country.

Germany links review to a national payment route

Germany created a different gate for eligible digital health applications, known by the German abbreviation DiGA. Germany’s health ministry says physicians can prescribe qualifying apps and statutory health insurance pays for them after the Federal Institute for Drugs and Medical Devices assesses safety, function, quality, data security and data protection. An app may receive provisional reimbursement for one year while its manufacturer supplies evidence that it improves care.

This arrangement connects assessment with a defined payer, but only inside Germany’s statutory health insurance system. It does not transfer German coverage to Japan, Taiwan, the United States or another market.

Taiwan rights leave the public status unresolved

Shionogi’s June announcement confirms Taiwan development and commercialization rights but reports a launch only in Japan. The Taiwan Food and Drug Administration, the health ministry unit that registers medical devices for sale in the territory, publishes an issued-license dataset that it says is synchronized weekly with its registration system. APPI News could not find ENDEAVORRIDE or EndeavorRx in the public sources it could access. It also could not verify whether Shionogi or another party had submitted an application that had not produced a public license record.

The distinction matters because rights, an application and an issued license are three different stages. Public license data can establish that a named product has a license, but a missing entry cannot establish what may be happening in a nonpublic review.

Regulatory clearance does not secure commercial continuity

Pear Therapeutics shows the difference between regulatory entry and a durable business. Its US annual report recorded $4.2 million in 2021 revenue, more than 14,000 prescriptions, a fulfillment rate of about 51 percent and 31.7 million covered lives. Those measures did not mean that every prescription became a paid, activated course of treatment.

Pear reported filing for Chapter 11 protection on April 7, 2023 and said it would seek a sale of the company or its assets. The sequence shows that authorization, payer reach, clinician prescribing, patient activation and company financing remain separate constraints. It is one company’s record and does not establish that other digital-therapeutics businesses will follow the same course.

Frequently asked questions

Is every health app a digital therapeutic?
No. The US study used a narrow definition covering prescription, software-only medical devices, while general-wellness apps and products requiring extra hardware were outside its count. Other countries use their own legal categories and evidence rules.

Is ENDEAVORRIDE authorized for sale in Taiwan?
APPI News could not verify an issued Taiwan license or a public filing as of August 12, 2026. The absence of a discoverable license does not prove that no application exists because the public dataset does not describe every possible step before a license is issued.

Does authorization in one country carry into another?
No. Shionogi’s Japan authorization, its Taiwan commercial rights and Germany’s reimbursement system are separate legal and payment arrangements. Availability and regulatory status vary by country.